mar
2020

Cancer Immunotherapy's approach

The rate limiting step in the Cancer Immunity Cycle is the capture of cancer antigens by Dendritic cells and their presentation to naive, antigen-specific T-cells to activate these to become cytotoxic T-cells (CTLs)

Ci's approach overcomes this rate limiting step by fusing cells from the patient's cancer directly to the patients DCs. This puts all the cancer antigens directly into the DCs enabling efficient activation of all the naive T-cells that recognise these antigens

Learn more

18
Mar
2025

Scientific Rationale: why cancer immunotherapy works

Cancer Immunotherapy approaches utilise the cancer immunity cycle that generates cytotoxic T-cells (CTLs) that recognise cancer antigens and are capable of eliminating tumour cells in patients.

There are two points of control of the cancer immunity cycle in normal physiology:

1. Capture and presentation of cancer antigens by DCs (these APCs are designed to capture cellular components and NOT intact cells)

2. Control checkpoint that limit the motility and migration of CTLs (PD1) or inactivate activated CTLs (CTLA-4)

Under normal conditions, the rate limiting step in the cancer immunity cycle is the capture and presentation of cancer antigens by DCs

VIEW

mar
2025

Cancer Immunotherapy's approach

The rate limiting step in the Cancer Immunity Cycle is the capture of cancer antigens by Dendritic cells and their presentation to naive, antigen-specific T-cells to activate these to become cytotoxic T-cells (CTLs)

Ci's approach overcomes this rate limiting step by fusing cells from the patient's cancer directly to the patients DCs. This puts all the cancer antigens directly into the DCs enabling efficient activation of all the naive T-cells that recognise these antigens

Learn more